Search
Vaccines Treatment Options
A collection of 953 research studies where Vaccines is the interventional treatment. These studies are located in the United States . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
349 - 360 of 953
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Completed
Primary Objective:
To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine:
* In Group 1 participants who were first vaccinated with 1 dose of MenACYW Conjugate vaccine 3-6 years before the booster dose.
* In Group 2 participants who were first vaccinated with 1 dose of Menveo vaccine (meningococcal \[Groups... Read More
Gender:
ALL
Ages:
Between 13 years and 26 years
Trial Updated:
09/15/2023
Locations: Investigational Site Number 8400012, Birmingham, Alabama +29 locations
Conditions: Meningococcal Immunisation (Healthy Volunteers)
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
PURPOSE: Phase II trial of vaccine therapy plus sargramostim following chemotherapy in tre... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/03/2023
Locations: Stanford University Medical Center, Stanford, California +1 locations
Conditions: Lymphoma
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Recruiting
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/01/2023
Locations: Kaiser Permanente Northern California (entire region), Oakland, California
Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
Completed
Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Completed
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen \[PSA\]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells that express PSA.
Gender:
MALE
Ages:
All
Trial Updated:
06/29/2023
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California +6 locations
Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: Indiana University Cancer Center, Indianapolis, Indiana +9 locations
Conditions: Prostate Cancer
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Completed
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Veterans Affairs Medical Center - Palo Alto, Palo Alto, California +64 locations
Conditions: Melanoma (Skin)
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
Completed
This pilot research trial studies the antibody response to high-dose seasonal influenza vaccination in patients with myeloid malignancy receiving chemotherapy and healthy volunteers. Evaluating antibody response to high-dose seasonal influenza vaccine may serve as a basis for vaccine recommendations in patients with myeloid malignancies and provide insights into the status of the immune system in these patients.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/02/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 225) Coastal Clinical Research, Mobile, Alabama +103 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Therapeutic Vaccination in Treated HIV Disease
Completed
The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target evolutionarily conserved epitopes. Our program is inspired by the recent success of VGX-3100 (Inovio), a DNA therapeutic vaccine for HPV that leads to histopathologic regression of pre-malignant lesions in people and is associated with a potent, sustained boost to HPV-speci... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/26/2023
Locations: University of California, Los Angeles, Los Angeles, California +1 locations
Conditions: HIV-1-infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
Completed
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in:
• People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
And
• People who have never had COVID-19 (SARS-CoV-2 infection).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: UCLA CARE Center CRS, Los Angeles, California +5 locations
Conditions: Covid19, SARS-CoV2 Infection
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Completed
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
05/18/2023
Locations: Eclipse Clinical Research, Tucson, Arizona +96 locations
Conditions: Pneumococcal Disease
349 - 360 of 953